Trials / Terminated
TerminatedNCT02888041
Is There an Interest in Repeating the Vaginal Administration of Dinoprostone (Propess®), to Promote Induction of Labor of Pregnant Women at Term?
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- University Hospital, Limoges · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
According perinatal surveys, induction of labor is performed at more than 20% of pregnant women. According to a survey on the trigger practices in France, prostaglandins are widely used to initiate cervical ripening, usually by laying intravaginal dinoprostone (Propess®). The overall work-up rate due to the use of a single Propess® is 74.6% with 80% of vaginal deliveries. Currently, 25.4% of patients who was not put in work after 24 hours are triggered by oxytocin (Syntocinon®) or directly caesarean. The initial installation of intravaginal dinoprostone limits the use of oxytocin (Syntocinon®) or in lower doses. Using a second Propess® is carried out in several maternity hospitals, as reported by the survey on the cervical ripening practices in France. This second administration could be the solution to reduce the rate of caesarean in France which amounted to 20.8%.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dinoprostone | In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient. |
| DRUG | Oxytocine | In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient. |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2022-04-23
- Completion
- 2022-04-23
- First posted
- 2016-09-02
- Last updated
- 2024-08-28
Locations
7 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02888041. Inclusion in this directory is not an endorsement.